An Automated and Qualified Platform Method for Site-Specific Succinimide and Deamidation Quantitation Using Low-pH Peptide Mapping.

analytical chemistry automation biopharmaceutical characterization deamidation liquid chromatography-mass spectrometry (LC-MS) mAb(s) physicochemical properties

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
11 2019
Historique:
received: 12 06 2019
revised: 26 07 2019
accepted: 26 07 2019
pubmed: 3 8 2019
medline: 9 9 2020
entrez: 3 8 2019
Statut: ppublish

Résumé

mAbs undergo several post-translational modifications, including the formation of succinimide from the deamidation of asparagine or the isomerization of aspartic acid. Because of the potential impact of succinimide formation on the biological activity of mAbs, detection and quantification of this species is a key area of interest for the pharmaceutical industry. However, studies assessing succinimide stability have been limited, and methods developed to monitor succinimide are either product specific or not robust. Here, we report the development of a platform low-pH peptide-mapping method using a combination of low-pH-resistant Lys-C and modified trypsin to maintain succinimide stability, eliminate deamidation assay artifact, and achieve efficient mAb digestion equivalent to conventional tryptic peptide-mapping method under alkaline condition. Using this method, succinimide stability in serum was accurately assessed in vitro study and the half-life was determined to be 1.5 days. With potential patient exposure to succinimide intermediate, a reliable method was developed to measure site-specific deamidation and succinimide intermediate. Coupled with a single quadrupole mass detector, our method was automated from digestion to data processing and applicable in a good manufacturing practice environment. The method was fully qualified to demonstrate accuracy, precision, linearity, and robustness.

Identifiants

pubmed: 31374319
pii: S0022-3549(19)30485-X
doi: 10.1016/j.xphs.2019.07.019
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Succinimides 0
succinimide 10X90O3503
Trypsin EC 3.4.21.4
Lysine K3Z4F929H6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3540-3549

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Mingyan Cao (M)

Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland 20878. Electronic address: mingyan.cao@astrazeneca.com.

Weichen Xu (W)

Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland 20878.

Ben Niu (B)

Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland 20878.

Ivy Kabundi (I)

Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland 20878.

Haibin Luo (H)

Department of Purification Process Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland 20878.

Meagan Prophet (M)

Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland 20878.

Weimin Chen (W)

Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland 20878.

Dengfeng Liu (D)

Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland 20878.

Sergei V Saveliev (SV)

Promega Corporation, Madison, Wisconsin 53711.

Marjeta Urh (M)

Promega Corporation, Madison, Wisconsin 53711.

Jihong Wang (J)

Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, Maryland 20878. Electronic address: jihongw@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH